Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.

Long KB, Young RM, Boesteanu AC, Davis MM, Melenhorst JJ, Lacey SF, DeGaramo DA, Levine BL, Fraietta JA.

Front Immunol. 2018 Dec 3;9:2740. doi: 10.3389/fimmu.2018.02740. eCollection 2018. Review.

2.

Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas.

Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, Cook DR, Thokala R, Blouch K, McGettigan-Croce B, Zhang L, Konradt C, Cogdill AP, Panjwani MK, Jiang S, Migliorini D, Dahmane N, Posey AD Jr, June CH, Mason NJ, Lin Z, O'Rourke DM, Johnson LA.

Mol Ther Oncolytics. 2018 Aug 28;11:20-38. doi: 10.1016/j.omto.2018.08.002. eCollection 2018 Dec 21.

3.

Transcriptome Analysis of Infected and Bystander Type 2 Alveolar Epithelial Cells during Influenza A Virus Infection Reveals In Vivo Wnt Pathway Downregulation.

Hancock AS, Stairiker CJ, Boesteanu AC, Monzón-Casanova E, Lukasiak S, Mueller YM, Stubbs AP, García-Sastre A, Turner M, Katsikis PD.

J Virol. 2018 Oct 12;92(21). pii: e01325-18. doi: 10.1128/JVI.01325-18. Print 2018 Nov 1.

4.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, Melenhorst JJ.

Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30.

5.

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.

Posey AD Jr, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, Cogdill AP, Chen TJ, Song D, Scholler J, Kranz DM, Feldman MD, Young R, Keith B, Schreiber H, Clausen H, Johnson LA, June CH.

Immunity. 2016 Jun 21;44(6):1444-54. doi: 10.1016/j.immuni.2016.05.014.

6.

Rapid Evolution of the CD8+ TCR Repertoire in Neonatal Mice.

Carey AJ, Gracias DT, Thayer JL, Boesteanu AC, Kumova OK, Mueller YM, Hope JL, Fraietta JA, van Zessen DB, Katsikis PD.

J Immunol. 2016 Mar 15;196(6):2602-13. doi: 10.4049/jimmunol.1502126. Epub 2016 Feb 12.

7.

Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections.

Gracias DT, Boesteanu AC, Fraietta JA, Hope JL, Carey AJ, Mueller YM, Kawalekar OU, Fike AJ, June CH, Katsikis PD.

J Immunol. 2016 Feb 1;196(3):1186-98. doi: 10.4049/jimmunol.1501890. Epub 2016 Jan 6.

8.

Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.

Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD Jr, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, Maus MV.

Sci Transl Med. 2015 Feb 18;7(275):275ra22. doi: 10.1126/scitranslmed.aaa4963.

9.

Abasic phosphorothioate oligomers inhibit HIV-1 reverse transcription and block virus transmission across polarized ectocervical organ cultures.

Fraietta JA, Mueller YM, Lozenski KL, Ratner D, Boesteanu AC, Hancock AS, Lackman-Smith C, Zentner IJ, Chaiken IM, Chung S, LeGrice SF, Snyder BA, Mankowski MK, Jones NM, Hope JL, Gupta P, Anderson SH, Wigdahl B, Katsikis PD.

Antimicrob Agents Chemother. 2014 Dec;58(12):7056-71. doi: 10.1128/AAC.02991-14. Epub 2014 Sep 15.

10.

Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection.

Fraietta JA, Mueller YM, Yang G, Boesteanu AC, Gracias DT, Do DH, Hope JL, Kathuria N, McGettigan SE, Lewis MG, Giavedoni LD, Jacobson JM, Katsikis PD.

PLoS Pathog. 2013;9(10):e1003658. doi: 10.1371/journal.ppat.1003658. Epub 2013 Oct 10.

11.

The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling.

Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, Mueller YM, Fraietta JA, Wherry EJ, Turner M, Katsikis PD.

Nat Immunol. 2013 Jun;14(6):593-602. doi: 10.1038/ni.2576. Epub 2013 Apr 21.

12.

The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis.

Artlett CM, Sassi-Gaha S, Rieger JL, Boesteanu AC, Feghali-Bostwick CA, Katsikis PD.

Arthritis Rheum. 2011 Nov;63(11):3563-74. doi: 10.1002/art.30568.

13.

Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo.

Dolfi DV, Duttagupta PA, Boesteanu AC, Mueller YM, Oliai CH, Borowski AB, Katsikis PD.

J Immunol. 2011 Apr 15;186(8):4599-608. doi: 10.4049/jimmunol.1001972. Epub 2011 Mar 9.

14.

Biopolymer encapsulated live influenza virus as a universal CD8+ T cell vaccine against influenza virus.

Boesteanu AC, Babu NS, Wheatley M, Papazoglou ES, Katsikis PD.

Vaccine. 2010 Dec 16;29(2):314-22. doi: 10.1016/j.vaccine.2010.10.036. Epub 2010 Oct 27.

15.

Phosphorothioate 2' deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1.

Fraietta JA, Mueller YM, Do DH, Holmes VM, Howett MK, Lewis MG, Boesteanu AC, Alkan SS, Katsikis PD.

Antimicrob Agents Chemother. 2010 Oct;54(10):4064-73. doi: 10.1128/AAC.00367-10. Epub 2010 Jul 12.

16.

Costimulation signals for memory CD8+ T cells during viral infections.

Duttagupta PA, Boesteanu AC, Katsikis PD.

Crit Rev Immunol. 2009;29(6):469-86. Review.

17.

Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion.

Bucks CM, Norton JA, Boesteanu AC, Mueller YM, Katsikis PD.

J Immunol. 2009 Jun 1;182(11):6697-708. doi: 10.4049/jimmunol.0800997.

18.

Memory T cells need CD28 costimulation to remember.

Boesteanu AC, Katsikis PD.

Semin Immunol. 2009 Apr;21(2):69-77. doi: 10.1016/j.smim.2009.02.005. Epub 2009 Mar 5. Review.

19.

Late signals from CD27 prevent Fas-dependent apoptosis of primary CD8+ T cells.

Dolfi DV, Boesteanu AC, Petrovas C, Xia D, Butz EA, Katsikis PD.

J Immunol. 2008 Mar 1;180(5):2912-21.

20.

Memory CD8+ T cells require CD28 costimulation.

Borowski AB, Boesteanu AC, Mueller YM, Carafides C, Topham DJ, Altman JD, Jennings SR, Katsikis PD.

J Immunol. 2007 Nov 15;179(10):6494-503.

21.

Role of TCR specificity in CD4+ CD25+ regulatory T-cell selection.

Picca CC, Larkin J 3rd, Boesteanu A, Lerman MA, Rankin AL, Caton AJ.

Immunol Rev. 2006 Aug;212:74-85. Review.

PMID:
16903907
22.

Impact of effector cell differentiation on CD4+ T cells that evade negative selection by a self-peptide.

Boesteanu A, Rankin AL, Caton AJ.

Int Immunol. 2006 Jul;18(7):1017-27. Epub 2006 May 15.

PMID:
16702167
23.

Selection of CD4+CD25+ regulatory T cells by self-peptides.

Cozzo C, Lerman MA, Boesteanu A, Larkin J 3rd, Jordan MS, Caton AJ.

Curr Top Microbiol Immunol. 2005;293:3-23. Review.

PMID:
15981473
24.

CD4(+) CD25(+) regulatory T cell selection.

Caton AJ, Cozzo C, Larkin J 3rd, Lerman MA, Boesteanu A, Jordan MS.

Ann N Y Acad Sci. 2004 Dec;1029:101-14. Review.

PMID:
15681750
25.

The H4b minor histocompatibility antigen is caused by a combination of genetically determined and posttranslational modifications.

Yadav R, Yoshimura Y, Boesteanu A, Christianson GJ, Ajayi WU, Shashidharamurthy R, Stanic AK, Roopenian DC, Joyce S.

J Immunol. 2003 May 15;170(10):5133-42.

26.

Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide.

Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Holenbeck AE, Lerman MA, Naji A, Caton AJ.

Nat Immunol. 2001 Apr;2(4):301-6.

PMID:
11276200
28.

Thermolabile H-2Kb molecules expressed by transporter associated with antigen processing-deficient RMA-S cells are occupied by low-affinity peptides.

De Silva AD, Boesteanu A, Song R, Nagy N, Harhaj E, Harding CV, Joyce S.

J Immunol. 1999 Oct 15;163(8):4413-20.

29.

A molecular basis for how a single TCR interfaces multiple ligands.

Boesteanu A, Brehm M, Mylin LM, Christianson GJ, Tevethia SS, Roopenian DC, Joyce S.

J Immunol. 1998 Nov 1;161(9):4719-27.

30.

Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol.

Joyce S, Woods AS, Yewdell JW, Bennink JR, De Silva AD, Boesteanu A, Balk SP, Cotter RJ, Brutkiewicz RR.

Science. 1998 Mar 6;279(5356):1541-4.

31.
32.

CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4.

Mendiratta SK, Martin WD, Hong S, Boesteanu A, Joyce S, Van Kaer L.

Immunity. 1997 Apr;6(4):469-77.

33.

Supplemental Content

Loading ...
Support Center